Quince TherapeuticsQNCX
QNCX
About: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Employees: 36
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,875% more call options, than puts
Call options by funds: $79K | Put options by funds: $4K
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
3% more funds holding
Funds holding: 35 [Q4 2024] → 36 (+1) [Q1 2025]
0.28% more ownership
Funds ownership: 11.61% [Q4 2024] → 11.89% (+0.28%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
27% less capital invested
Capital invested by funds: $9.55M [Q4 2024] → $6.96M (-$2.6M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
138%
upside
Avg. target
$4
138%
upside
High target
$4
138%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 138%upside $4 | Buy Maintained | 17 Jul 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Tel.
Neutral
Business Wire
2 weeks ago
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). D.
Neutral
Business Wire
1 month ago
Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., ke.
Neutral
Business Wire
1 month ago
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”) that resulted in ap.
Neutral
Business Wire
1 month ago
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”).
Neutral
Business Wire
1 month ago
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a to.
Positive
Seeking Alpha
2 months ago
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results.
Neutral
Business Wire
2 months ago
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “In light of current cash runway and with the goal of maxim.
Neutral
Business Wire
3 months ago
Quince Therapeutics to Present at Citizens Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation.
Neutral
Business Wire
3 months ago
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025. A replay of the presentation will be accessible on the Events page under the Ne.
Charts implemented using Lightweight Charts™